Dexmedetomidine use and short-term all-cause mortality in ICU patients with ischemic stroke and atrial fibrillation: a propensity-matched analysis from MIMIC-IV

Q: What are the key findings of this study?

In ICU patients with ischemic stroke and atrial fibrillation, dexmedetomidine administration was associated with lower 7-day all-cause mortality (HR 0.26; 95% CI 0.12-0.54; P<0.001).

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: Ischemic stroke and atrial fibrillation (n=1355). Intervention: Dexmedetomidine (DEX) vs. No dexmedetomidine. Primary outcome: 7-day all-cause mortality (HR 0.26, 95% CI 0.12-0.54, p=<0.001).

Q: What does this research mean for the field?

Dexmedetomidine administration is significantly associated with reduced 7-day and 90-day all-cause mortality in ICU patients with ischemic stroke and atrial fibrillation. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To evaluate the connection between early dexmedetomidine administration and short-term all-cause mortality in intensive care unit patients diagnosed with ischemic stroke and atrial fibrillation.

Zengyan Bai; Ke Shi; Hongwei Liu; Zhinan Ye; Suqian Xu

doi:10.1159/ene/acsag008

September 17, 2026European NeurologyOpen Access

Dexmedetomidine use and short-term all-cause mortality in ICU patients with ischemic stroke and atrial fibrillation: a propensity-matched analysis from MIMIC-IV

View Full Paper

Ask AI

Bookmark

Share

Key result

Dexmedetomidine is linked to ~74% lower 7-day mortality in ICU patients with stroke and AF.

HR 0.26
95% CI 0.12-0.54
P<0.001
n=1,355

Why the study?

The potential protective role and underlying mechanisms of dexmedetomidine in ischemic stroke patients with atrial fibrillation remain unclear.

Does early administration of dexmedetomidine reduce short-term mortality in ICU patients with ischemic stroke and atrial fibrillation?

Key Points

To evaluate the connection between early dexmedetomidine administration and short-term all-cause mortality in intensive care unit patients diagnosed with ischemic stroke and atrial fibrillation.
Extracted data from the MIMIC-IV database for 1,355 ICU patients with ischemic stroke and atrial fibrillation, of whom 253 received dexmedetomidine.
Conducted 1:1 propensity score matching to balance baseline characteristics, yielding 208 matched patient pairs.
Evaluated 7-day (primary) and 90-day (secondary) all-cause mortality using Cox proportional hazards regression and Kaplan-Meier survival analyses.
Dexmedetomidine use was significantly associated with decreased 7-day all-cause mortality before matching (HR=0.36, 95% CI: 0.19–0.68, P=0.002) and after propensity score matching (HR=0.26, 95% CI: 0.12–0.54, P<0.001).
Dexmedetomidine treatment was associated with lower 90-day all-cause mortality after matching (HR=0.72, 95% CI: 0.53–0.97, P=0.031; before matching HR=0.84, 95% CI: 0.66–1.07, P=0.162).
Subgroup analyses demonstrated stronger protective associations among females, individuals aged 70 and older, patients with hypertension, and those without chronic kidney disease or heart failure.

Study Design

Type

Cohort (n=1,355)

Structured PICO

Does early administration of dexmedetomidine reduce short-term mortality in ICU patients with ischemic stroke and atrial fibrillation?

P

Population

1,355 ICU patients with ischemic stroke and atrial fibrillation from the MIMIC-IV database, evaluated for the association between dexmedetomidine use and short-term mortality.

E

Exposure

Early administration of dexmedetomidine (DEX)

C

Comparator

No dexmedetomidine administration

O

Outcome

7-day all-cause mortalityhard clinical

Main Result

Hazard Ratio: 0.26 (95% CI 0.12–0.54)

p-value: p=<0.001

In ICU patients with ischemic stroke and atrial fibrillation, early administration of dexmedetomidine is associated with a significant reduction in 7-day and 90-day all-cause mortality.

Implication

Should not yet change sedation practices in stroke-AF ICU patients; hypothesis-generating data extends preclinical signals and requires RCT confirmation.

Abstract

Introduction Preclinical studies have demonstrated that dexmedetomidine (DEX), a sedative widely used in intensive care units (ICUs), exerts neuroprotective effects. However, its potential protective role and underlying mechanisms in ischemic stroke patients with atrial fibrillation (AF) remain unclear. The study's objective was to assess the connection between the early administration of DEX and short-term mortality from all causes in patients with ischemic stroke and AF. Methods From the MIMIC-IV database, patients with ischemic stroke and AF were identified, including those who were administered DEX and those who were not. The primary endpoint was 7-day all-cause mortality, and the secondary endpoint was 90-day all-cause mortality. Propensity score matching (PSM) was utilized to ensure baseline covariates were balanced. Cox proportional hazards models and Kaplan-Meier survival curves and were utilized to evaluate the association between dexmedetomidine (DEX) use and mortality, with subgroup analyses conducted to ensure the findings' robustness. Results In total, 1,355 patients with ischemic stroke and AF participated, with 253 (18.7%) receiving DEX. After PSM, 208 pairs were matched. In the fully adjusted model, dexmedetomidine (DEX) administration was significantly associated with lower all-cause mortality compared with the control group at both 7 days (before PSM, HR=0.36, 95%CI: 0.19-0.68, P=0.002; after PSM, HR=0.26, 95%CI: 0.12-0.54, P<0.001) and 90 days (before PSM, HR=0.84, 95%CI: 0.66-1.07, P=0.162; after PSM, HR=0.72, 95%CI: 0.53- 0.97, P=0.031). The subgroup analyses revealed that DEX's protective effect was stronger in patients aged 70 and above, females, those with hypertension, and those without heart failure or chronic kidney disease. Kaplan-Meier survival curves consistently illustrated that DEX users had greater survival probabilities both before and after matching. Conclusion In patients with ischemic stroke complicated by AF, DEX administration is connected to decreased mortality, underlining the possible importance of DEX in ICU settings.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bai et al. (2026) conducted a cohort in Ischemic stroke and atrial fibrillation (n=1,355). Dexmedetomidine (DEX) vs. No dexmedetomidine was evaluated on 7-day all-cause mortality (HR 0.26, 95% CI 0.12-0.54, p=<0.001). In ICU patients with ischemic stroke and atrial fibrillation, dexmedetomidine administration was associated with lower 7-day all-cause mortality (HR 0.26; 95% CI 0.12-0.54; P<0.001).

synapsesocial.com/papers/6ad2187bfc66cec880534e68 https://doi.org/10.1159/ene/acsag008